Brief: Surrozen Q2 EPS USD 2.55

Surrozen

08/08/2025 21:06

Overview

Surrozen Q2 net income $39.7 mln, reversing loss from previous year

Company advances ophthalmology pipeline with SZN-8141 and SZN-8143

Cash position at $90.4 mln, down from previous quarter

Highlights in Q2

OPHTHALMOLOGY PIPELINE - Progress on lead candidates SZN-8141 and SZN-8143 for retinal diseases

Co notes it is on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026.

PATENT ISSUANCE - U.S. Patent granted for SWAP™ technology, strengthening intellectual property for SZN-8141 and SZN-8143

LEADERSHIP APPOINTMENT - Dr. Daniel Chao joins as VP of Clinical Development, bringing extensive expertise in ophthalmology

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
$2.55
Q2 Net Income
$39.75 mln
Q2 Operating Expenses
$10 mln
Q2 Operating Income
-$9.02 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Surrozen Inc is $37.00, about 75.6% above its August 7 closing price of $9.03

Press Release: ID:nGNX1gqX8F

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)